Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus.
Biomarker
Cerebrospinal fluid (CSF)
Neurodestruction
Neurofilament light (NfL)
Status epilepticus (SE)
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
02
10
2022
accepted:
23
12
2022
revised:
22
12
2022
pubmed:
10
1
2023
medline:
22
3
2023
entrez:
9
1
2023
Statut:
ppublish
Résumé
We explored the potential of neurofilament light chain (NfL) in serum and cerebrospinal fluid as a biomarker for neurodestruction in status epilepticus. In a retrospective analysis, we measured NfL in serum and cerebrospinal fluid samples of patients with status epilepticus using a highly sensitive single-molecule array technique (Simoa). Status epilepticus was diagnosed according to ILAE criteria. Additionally, we employed an alternative classification with more emphasis on the course of status epilepticus. We used data from three large control groups to compare NfL in status epilepticus versus neurologically healthy controls. We included 28 patients (mean age: 69.4 years, SD: 15 years) with a median status duration of 44 h (IQR: 80 h). Twenty-one patients (75%) suffered from convulsive status epilepticus and seven (25%) from non-convulsive status epilepticus. Six patients died (21%). Cerebrospinal fluid and serum NfL concentrations showed a high correlation (r = 0.73, p < 0.001, Pearson). The main determinant of NfL concentration was the status duration. NfL concentrations did not differ between convulsive status epilepticus and convulsive status epilepticus classified according to the ILAE or to the alternative classification without and with adjusting for status duration and time between status onset and sampling. We found no association of NfL concentration with death, treatment refractoriness, or prognostic scores. The results suggest that neurodestruction in status epilepticus measured by NfL is mainly determined by status duration, not status type nor therapy refractoriness. Therefore, our results suggest that regarding neurodestruction convulsive and non-convulsive status epilepticus are both neurological emergencies of comparable urgency.
Identifiants
pubmed: 36624182
doi: 10.1007/s00415-022-11547-4
pii: 10.1007/s00415-022-11547-4
pmc: PMC10025237
doi:
Substances chimiques
Neurofilament Proteins
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2128-2138Informations de copyright
© 2023. The Author(s).
Références
Neurology. 1999 Nov 10;53(8):1761-4
pubmed: 10563625
Seizure. 2020 Feb;75:115-120
pubmed: 31945716
JAMA Neurol. 2019 Mar 1;76(3):318-325
pubmed: 30508027
J Neurol. 2008 Oct;255(10):1561-6
pubmed: 18769858
Front Neurosci. 2021 Jun 21;15:679199
pubmed: 34234641
Community Genet. 2006;9(1):55-61
pubmed: 16490960
Epilepsia. 2018 Apr;59(4):739-744
pubmed: 29399791
Int Rev Neurobiol. 2007;81:287-97
pubmed: 17433932
Nat Biotechnol. 2010 Jun;28(6):595-9
pubmed: 20495550
Arch Neurol. 1973 Jan;28(1):10-7
pubmed: 4629379
Epilepsy Behav. 2015 Aug;49:158-63
pubmed: 26092326
BMC Psychiatry. 2014 Jun 13;14:174
pubmed: 24924233
Mol Biol Rep. 2014 Jun;41(6):4017-22
pubmed: 24733614
Neurology. 2006 Jun 13;66(11):1736-8
pubmed: 16769951
Epilepsia. 2020 Jan;61(1):6-18
pubmed: 31828792
Neurology. 2018 Oct 9;91(15):e1390-e1401
pubmed: 30209235
Curr Opin Crit Care. 2005 Apr;11(2):117-20
pubmed: 15758590
Eur J Neurol. 2022 Mar;29(3):883-889
pubmed: 34687105
Front Neurol. 2019 Apr 05;10:338
pubmed: 31024432
Epilepsia. 2022 Jan;63(1):e23-e29
pubmed: 34806176
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Epilepsy Curr. 2004 Jan;4(1):25-27
pubmed: 15346141
Eur J Neurol. 2021 Aug;28(8):2694-2699
pubmed: 33932068
Epilepsia. 2010 Feb;51(2):251-6
pubmed: 19817823
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Epilepsy Behav. 2015 Aug;49:203-22
pubmed: 26148985
Epilepsia. 2001 Apr;42(4):504-7
pubmed: 11440345
Acta Neurol Scand. 2014 Jun;129(6):405-11
pubmed: 24571568
Arch Neurol. 1973 Aug;29(2):82-7
pubmed: 4197956
Neurocrit Care. 2015 Apr;22(2):273-82
pubmed: 25412806
World J Oncol. 2019 Oct;10(4-5):169-175
pubmed: 31636790
Neurosci Biobehav Rev. 2021 Dec;131:834-846
pubmed: 34517036
J Neurol. 2022 Jul;269(7):3752-3760
pubmed: 35190890
Brain Pathol. 1993 Oct;3(4):405-12
pubmed: 8293196
BMC Med. 2021 Feb 15;19(1):38
pubmed: 33583409
Neurology. 2020 Aug 11;95(6):e623-e636
pubmed: 32641529
Epilepsia. 2019 Jan;60(1):53-62
pubmed: 30478910
Epilepsy Behav. 2020 Feb;103(Pt A):106720
pubmed: 31902646
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
Epilepsy Res. 2006 Jan;68 Suppl 1:S77-82
pubmed: 16384688
PLoS One. 2015 Jul 02;10(7):e0132177
pubmed: 26136237
Clin Neurophysiol Pract. 2019 Aug 09;4:170-177
pubmed: 31886441
BMC Neurol. 2010 Jun 22;10:51
pubmed: 20569437
Crit Care. 2016 Jan 27;20:25
pubmed: 26812954